Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura

  • Technology appraisal guidance
  • TA667
  • Published: 

History

Documents created during the development process.

Expected publication

Declaration of interests

Final draft guidance

Draft guidance: 1

Invitation to participate